xylyx

In Matrico®
Research Tools & Services

developing and leveraging advanced tissue models
that incorporate native cellular microenvironments

Products

TissueSpec® ECM biomaterials enable the development of physiologic tissue models.

Services

In Matrico® drug testing improves decision making through clinically-relevant results.

Tissue-Specific ECMs

News

Researchers confirm successful rehabilitation and recovery of human donor lungs previously deemed unfit for transplant

A cross-disciplinary team of surgeons and bioengineers from Vanderbilt University, Columbia University, Stanford University, New York-Presbyterian Hospital, State University of New York Downstate Medical Center, and Xylyx Bio collaborated to develop a new technique called ‘xenogeneic cross-circulation’, which involves temporarily connecting a human donor lung to a live pig to support and resuscitate the human […]

Read More

Xylyx Bio collaboration reveals new insights into tumor drug resistance

Researchers at the University of Illinois applied Xylyx Bio’s IN SITE Metastasis Kit to evaluate a cancer therapeutic. Molecular Cancer Research, a journal of the American Association for Cancer Research, recently published the peer-reviewed manuscript. The results showed that dietary interventions may increase the efficacy of treatment for breast cancer metastases. Read the Publication! Watch […]

Read More

Xylyx Bio Awarded $2.2M NIH SBIR Fast-Track Grant from National Heart, Lung, and Blood Institute

Xylyx Bio has been awarded a Small Business Innovation Research (SBIR) Fast-Track grant from the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to advance development of an anti-fibrotic drug testing platform that will help scientists discover and test drug candidates for idiopathic pulmonary fibrosis (IPF).

Read More

Xylyx Bio partners with Inventia Life Science to develop tissue-specific, digitally-printed bioinks for drug discovery

Xylyx Bio, a New York-based leader in advanced biomaterials, and Inventia Life Science, a Sydney-based biotechnology company, today announced their strategic partnership following promising results developing more realistic, scalable, and reproducible 3D cell cultures for drug discovery and biomedical research.

Read More

What they’re saying

“ We were looking for a product to use for engineering cartilage tissue. We used the TissueSpec® Cartilage ECM Hydrogel to encapsulate chondrocytes within the 3D tissue environment the cells are exposed to in native cartilage. Chondrocytes grew really well, and these tissue constructs have developed mechanical and biochemical properties and histological staining similar to native articular cartilage.”
Bob Nims, PhD, Columbia University